All-new research in dermatology is available now – take a look at this month’s new and exclusive content on JDDonline.com:
- In a multicenter clinical study, investigators conduct an analysis of data on the Effect of Calcipotriene/Betamethasone Dipropionate 0.005%/0.064% Foam on Target Lesions in Plaque Psoriasis: A Post-Hoc Analysis
-
Authors evaluate Intralesional Triamcinolone Acetonide in the Treatment of Traction Alopecia in a retrospective chart review of TA patients treated with ILK at an academic dermatology clinic.
-
Real-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab highlights the safety and efficacy and unique mechanisms of action of the IL-17 inhibitors.
-
Real-World Clinical Experience With the IL-17 Receptor A Antagonist Brodalumab highlights the safety and efficacy and unique mechanisms of action of the IL-17 inhibitors.
- The IL-17 pathway plays a crucial role in the immunopathogenesis and development of psoriasis in Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis.
-
A Survey of Dermatologists’ Preparedness for Natural and Manmade Disasters examines whether the dermatology field has advanced in its bioterrorism preparedness since a 2003 survey revealed 88% of dermatologists felt unprepared to respond to a biological attack.
View all February JDD content, including editor’s picks, supplements, CME activities, case reports, and more!
Read Now
You May Also Like
JDD Re:View With Dr. Beer
JDD Re:View With Dr. Beer
Hair Disorders and Treatments Hair treatments have proliferated in the past several years. While prior treatment options were limited to topical minoxidil and oral finasteride for androgenetic alopecia (AGA),…
Proximal Subungual Onychomycosis in the Immunocompetent: A Case Report and Review of the Literature
Proximal Subungual Onychomycosis in the Immunocompetent: A Case Report and Review of the Literature
From the Vault: Pulled due to increased interest in rare onychomycosis presentations This case report dates back to JDD’s April 2018 issue. It’s a case report describing a healthy 51-year-old…
Brodalumab’s 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence
Brodalumab’s 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence
Updated long term and real world evidence on efficacy and safety This is a must-read JDD article on brodalumab in plaque psoriasis. The review summarizes long term clinical trial findings,…
